NCT00268593 - Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions

Prostate Cancer

Interventions

DRUG

PI-88

Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.

DRUG

docetaxel

Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.

DRUG

prednisone

5 mg twice a day orally

Trial Locations (8)

2031

Liverpool Cancer Therapy Centre, Randwick

2065

Royal North Shore Hospital, St Leonards

2077

Sydney Haematology and Oncology Clinics, Hornsby

2217

St George Hospital, Kogarah

2444

Port Macquarie Base Hospital, Port Macquarie

2477

Lismore Base Hospital, Lismore

3690

Border Medical Oncology, Wodonga

5035

Ashford Cancer Centre, Ashford